Patent ID: 9181345
Filing Date: 2015-11-10
Classification: A61K,A61P,C07K,C12Q,G01N

Abstract:
1. A method of treating a patient having lupus comprising: administering an effective amount of an antibody that binds to and decreases or inhibits type I IFN or IFNα activity; wherein the patient having lupus comprises autoantibodies that bind at least any three or more auto-antigens of: (a) Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78; (b) surfeit 5, transcript variant c; (c) proteasome (posome, macropain) activator subunit 3 (PA28 gamma; Ki) transc; (d) retinoic acid receptor, alpha; (e) Heat shock 10 kDa protein 1 (chaperonin 10); (f) Tropomyosin 3; (g) Pleckstrin homology-like domain, family A, member 1; (h) Cytoskeleton-associated protein 1; (i) Sjogren syndrome antigen A2 (60 kDa, ribonucleoprotein auto-antigen SS-A/Ro); (j) NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex 1, 8 kDa; (k) NudE nuclear distribution gene E homolog 1 ( (l) MutL homolog 1, colon cancer, nonpolyposis type 2 ( (m) leucine rich repeat (in FLII) interacting protein 2; (n) tropomyosin 1 (alpha); (o) spastic paraplegia 20, spartin (Troyer syndrome); (p) preimplantation protein, transcript variant 1; (q) mitochondrial ribosomal protein L45; and (r) fumarate hydratase and wherein the agent reduces the number or levels of the auto-antibodies that bind at least any three auto-antigens in the patient.